REFRACTORY MULTIPLE MYELOMA
Clinical trials for REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat myeloma
Disease control TerminatedThis early-phase trial tested a new drug called KRT-232 combined with three standard myeloma drugs (carfilzomib, lenalidomide, and dexamethasone) in 35 patients whose multiple myeloma had returned or stopped responding to treatment. The main goals were to check safety and find th…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental CAR t therapy targets tough myeloma cases
Disease control TerminatedThis early study tested a new treatment called Descartes-15 for people with multiple myeloma that came back or didn't respond to standard therapies. Descartes-15 uses a patient's own immune cells, engineered to recognize and attack myeloma cells. The trial was very small (4 parti…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Prehab before CAR-T: can a simple exercise program boost outcomes for myeloma patients?
Knowledge-focused TerminatedThis study tests whether a personalized exercise program (aerobic and resistance training) done before CAR-T therapy can improve physical fitness and quality of life in older adults (60+) with multiple myeloma that has returned or stopped responding to treatment. Twenty participa…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jul 02, 2026 02:00 UTC